Abstract
Regulating clinical stem cell research, which has been one of the most ethically controversial technologies of the present age, is an unenviable task for China. The ambit of the Administrative Measure is wide. The Chinese government hopes to rein the clinical stem cell research with the enforcement of the new order. However, the legal framework of clinical stem cell therapy leaves a door open for untested and unverified stem cell therapies. And it is still an open question whether the combination of the Ministry of Health and CFDA is capable of enforcing the Administrative Measures on hospitals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
